{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:18:22Z","timestamp":1793452702315,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-75292-6","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T05:02:05Z","timestamp":1730523725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Virtual screening, ADMET prediction, molecular docking, and dynamic simulation studies of natural products as BACE1 inhibitors for the management of Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"14","author":[{"given":"Davood","family":"Gheidari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Mehrdad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"karimelahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"key":"75292_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41582-024-00940-4","volume":"20","author":"AD Korczyn","year":"2024","unstructured":"Korczyn, A. D. & Grinberg, L. T. Is Alzheimer disease a disease? Nat. Rev. Neurol. 20, 245\u2013251 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"75292_CR2","doi-asserted-by":"crossref","unstructured":"Gheidari, D. & Bayat, M. Current treads of targeted nanoparticulate carriers for the treatment of Alzheimer\u2019s disease. Acad. Press. 17\u201339 (2022).","DOI":"10.1016\/B978-0-323-85544-0.00005-8"},{"key":"75292_CR3","doi-asserted-by":"crossref","unstructured":"DeTure, M. A. & Dickson, D. W. The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener. 2, 14(1)-32 (2019).","DOI":"10.1186\/s13024-019-0333-5"},{"key":"75292_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13195-019-0529-5","volume":"11","author":"J Cummings","year":"2019","unstructured":"Cummings, J., Feldman, H. H. & Scheltens, P. The rights of precision drug development for Alzheimer\u2019s disease. Alz Res. Ther. 11, 76 (2019).","journal-title":"Alz Res. Ther."},{"key":"75292_CR5","doi-asserted-by":"crossref","unstructured":"Song, K. et al. Oxidative stress-mediated blood-brain barrier (BBB) disruption in neurological diseases. Oxid. Med. Cell. Longev. e4356386 (2020). (2020).","DOI":"10.1155\/2020\/4356386"},{"key":"75292_CR6","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fnins.2023.1219299","volume":"17","author":"D Lamontagne-Kam","year":"2023","unstructured":"Lamontagne-Kam, D., Ulfat, A. K., Herv\u00e9, V., Vu, T. M. & Brouillette, J. Implication of tau propagation on neurodegeneration in Alzheimer\u2019s disease. Front. NeuroSci. 17, 1662\u2013453X (2023).","journal-title":"Front. NeuroSci."},{"key":"75292_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y., Chen, H., Li, R., Sterlin, K. & Song, W. Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: Challenges, successes and future. Sig Transduct. Target. Ther. 8, 248 (2023).","journal-title":"Sig Transduct. Target. Ther."},{"issue":"1","key":"75292_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/med.21622","volume":"40","author":"NM Moussa-Pacha","year":"2020","unstructured":"Moussa-Pacha, N. M., Abdin, S. M., Omar, H. A., Alniss, H. & Al-Tel, T. H. BACE1 inhibitors: Current status and future directions in treating Alzheimer\u2019s disease. Med. Res. Rev. 40(1), 339\u2013384 (2020).","journal-title":"Med. Res. Rev."},{"key":"75292_CR9","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/life13040952","volume":"13","author":"K Chidambaram","year":"2023","unstructured":"Chidambaram, K. Identification of BACE-1 inhibitors against Alzheimer\u2019s disease through E-pharmacophore-based virtual screening and molecular dynamics simulation studies: An insilco approach. Life 13, 952 (2023).","journal-title":"Life"},{"key":"75292_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40263-019-00613-7","volume":"33","author":"B Das","year":"2019","unstructured":"Das, B. & Yan, R. A. Close look at BACE1 inhibitors for Alzheimer\u2019s disease treatment. CNS Drugs 33, 251\u2013263 (2019).","journal-title":"CNS Drugs"},{"key":"75292_CR11","doi-asserted-by":"publisher","first-page":"eabo3610","DOI":"10.1126\/sciadv.abo3610","volume":"8","author":"N Singh","year":"2022","unstructured":"Singh, N. et al. BACE-1 inhibition in microglia enhances amyloid clearance and improved cognitive performance. Sci. Adv. 8, eabo3610 (2022).","journal-title":"Sci. Adv."},{"key":"75292_CR12","doi-asserted-by":"crossref","unstructured":"Murray, A., Mu\u00f1iz-Garc\u00eda, A., Ali\u0107, I. & Ni\u017eeti\u0107, D. It\u2019s good to know what to BACE the specificity of your inhibitors on. Clin. Invest. 134(16), e183677 (2024).","DOI":"10.1172\/JCI183677"},{"issue":"12","key":"75292_CR13","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1093\/brain\/awaa332","volume":"143","author":"C Sur","year":"2020","unstructured":"Sur, C. et al. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer\u2019s disease brain. Brain Neurol. 143(12), 3816\u20133826 (2020).","journal-title":"Brain Neurol."},{"key":"75292_CR14","first-page":"0223","volume":"221","author":"PS Jo\u00e3o","year":"2021","unstructured":"Jo\u00e3o, P. S. et al. Dual-target compounds for Alzheimer\u2019s disease: natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR). Med. Chem. 221, 0223\u20135234 (2021).","journal-title":"Med. Chem."},{"key":"75292_CR15","first-page":"1483","volume":"16","author":"AM Wessels","year":"2020","unstructured":"Wessels, A. M. et al. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer\u2019s disease. Alzheimer\u2019s Assoc. 16, 1483\u20131492 (2020).","journal-title":"Alzheimer\u2019s Assoc."},{"key":"75292_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12929-023-00976-6","volume":"30","author":"LK Huang","year":"2023","unstructured":"Huang, L. K., Kuan, Y. C., Lin, H. W. & Hu, C. J. Clinical trials of new drugs for Alzheimer disease: 2020\u20132023 update. J. Biomed. Sci. 30, 83 (2023).","journal-title":"J. Biomed. Sci."},{"issue":"22","key":"75292_CR17","first-page":"3905","volume":"13","author":"SY Jeon","year":"2003","unstructured":"Jeon, S. Y., Bae, K., Seong, Y. H. & Song, K. S. Green tea catechins as a BACE1 (\u03b2-Secretase) inhibitor. BMCL. 13(22), 3905\u20133908 (2003).","journal-title":"BMCL"},{"key":"75292_CR18","doi-asserted-by":"crossref","unstructured":"Li, D. D., Zhang, Y. H., Zhang, W. & Zhao, P. Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease. Front. Neurosci. (2019).","DOI":"10.3389\/fnins.2019.00472"},{"key":"75292_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3390\/ddc2020017","volume":"2","author":"TA Oliveira","year":"2023","unstructured":"Oliveira, T. A., Silva, M. P., Maia, E. H. B., Silva, A. M. & Taranto, A. G. Virtual screening algorithms in drug discovery: A review focused on machine and deep learning methods. DDC 2, 311\u2013334 (2023).","journal-title":"DDC"},{"issue":"7","key":"75292_CR20","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1021\/ci3001277","volume":"52","author":"JJ Irwin","year":"2012","unstructured":"Irwin, J. J. et al. A free tool to discover chemistry for biology. J. Chem. Inf. Model. 52(7), 1757\u20131768 (2012).","journal-title":"J. Chem. Inf. Model."},{"key":"75292_CR21","unstructured":"https:\/\/www.rcsb.org"},{"key":"75292_CR22","unstructured":"Biovia, D. et al. (2016). Dassault Syst emes BIOVIA, Discovery Studio Visualizer, v. 17.2. Dassault Systemes."},{"key":"75292_CR23","doi-asserted-by":"crossref","unstructured":"LigPrep Schr\u00f6dinger Release 2017-1: LigPrep (Schr\u00f6dinger, LLC, 2017).","DOI":"10.2307\/j.ctvcm4h07.63"},{"issue":"3","key":"75292_CR24","doi-asserted-by":"publisher","first-page":"e0299301","DOI":"10.1371\/journal.pone.0299301","volume":"19","author":"D Gheidari","year":"2024","unstructured":"Gheidari, D., Mehrdad, M. & Bayat, M. Synthesis, molecular docking analysis, molecular dynamic simulation, ADMET, DFT, and drug likeness studies: Novel Indeno [1,2-b]pyrrol-4(1H)-one as SARS-CoV-2 main protease inhibitors. PLoS ONE 19(3), e0299301 (2024).","journal-title":"PLoS ONE"},{"key":"75292_CR25","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1038\/s41598-024-53514-1","volume":"14","author":"D Gheidari","year":"2024","unstructured":"Gheidari, D., Mehrdad, M., Bayat, M. & Synthesis Docking, MD simulation, ADMET, drug likeness, and DFT studies of novel furo [2,3-b] indol-3a-ol as promising cyclin-dependent kinase 2 inhibitors. Sci. Rep. 14, 3084 (2024).","journal-title":"Sci. Rep."},{"key":"75292_CR26","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 42717 (2017).","journal-title":"Sci. Rep."},{"key":"75292_CR27","unstructured":"ADMETlab 2.0, https:\/\/admetmesh.scbdd.com\/, accessed 29 September 2021."},{"key":"75292_CR28","doi-asserted-by":"publisher","first-page":"101894","DOI":"10.1016\/j.jscs.2024.101894","volume":"28","author":"N Mahmoodi","year":"2024","unstructured":"Mahmoodi, N., Bayat, M., Gheidari, D. & Sadeghian, Z. In silico evaluation of cis-dihydroxy-indeno [1,2-d] imidazolones as inhibitors of glycogen synthase kinase-3: synthesis, molecular docking, physicochemical data, ADMET, MD simulation, and DFT calculations. J. Saudi Chem. Soc. 28, 101894 (2024).","journal-title":"J. Saudi Chem. Soc."},{"issue":"38","key":"75292_CR29","doi-asserted-by":"publisher","first-page":"24891","DOI":"10.1021\/acsomega.1c03736","volume":"6","author":"R Srivastava","year":"2021","unstructured":"Srivastava, R. Theoretical studies on the Molecular properties, toxicity, and Biological Efficacy of 21 New Chemical entities. ACS Omega. 6(38), 24891\u201324901 (2021).","journal-title":"ACS Omega"},{"issue":"3","key":"75292_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1021\/acs.jcim.6b00465","volume":"57","author":"SJ Capuzzi","year":"2017","unstructured":"Capuzzi, S. J., Muratov, E. N., Tropsha, A. & Phantom, P. A. I. N. S. Problems with the utility of alerts for Pan-assay INterference CompoundS. J. Chem. Inf. Model. 57(3), 417\u2013427 (2017).","journal-title":"J. Chem. Inf. Model."},{"issue":"1","key":"75292_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1021\/acschembio.7b00903","volume":"13","author":"JB Baell","year":"2018","unstructured":"Baell, J. B. & Nissink, J. W. M. Seven Year Itch: Pan-assay Interference compounds (PAINS) in 2017-Utility and limitations. ACS Chem. Biol. 13(1), 36\u201344 (2018).","journal-title":"ACS Chem. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75292-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75292-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75292-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T05:02:51Z","timestamp":1730523771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75292-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["75292"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-75292-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,2]]},"assertion":[{"value":"2 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26431"}}